DRMA 424B3: Secondary offering

Dermata Therapeutics

Filed with the SEC on Oct 21, 2026 · accession 0001493152-26-047911

DRMA filed a 424B3 (prospectus (offering)) with the SEC on Oct 21, 2026. Dermata Therapeutics filed a 424B3 resale prospectus covering up to 6,919,560 shares of common stock issued in a private placement that closed August 18, 2026, including shares and shares underlying pre-funded, Series E, Series F, and Bank warrants. The stock moved -8.1% by the first close after the filing.

Summary of the filing

Dermata Therapeutics filed a 424B3 resale prospectus covering up to 6,919,560 shares of common stock issued in a private placement that closed August 18, 2026, including shares and shares underlying pre-funded, Series E, Series F, and Bank warrants. The company will not receive proceeds from resales, but may receive proceeds from any cash exercise of the warrants.

For details, click here →How to read a 424B3 →

Key details

Total shares of common stock registered for resale$6.9M

Shares of common stock registered for resale$933K

Pre-funded warrant shares$1.4M

Series E warrant shares$2.3M

Series F warrant shares$2.3M

Bank warrant shares$36K

Exercise price of Series E and Series F warrants$1

Exercise price of Bank warrants$2

Last reported sale price of common stock on October 6, 2026$1

IssuerDermata Therapeutics, Inc.

How DRMA stock reacted

Close before

$0.87

Oct 20, 2026

First close after

-8.09%

$0.80

5 trading days

-13.21%

$0.76

Since filing

-12.17%

$0.76

✦ Ask GOAX AI about this filing — what it means for DRMA, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for DRMA?

Click here

Frequently asked questions

What did DRMA file with the SEC on Oct 21, 2026?

DRMA filed a 424B3 (Secondary offering). Dermata Therapeutics filed a 424B3 resale prospectus covering up to 6,919,560 shares of common stock issued in a private placement that closed August 18, 2026, including shares and shares underlying pre-funded, Series E, Series F, and Bank warrants. The company will not receive proceeds from resales, but may receive proceeds from any cash exercise of the warrants.

What does a secondary offering mean for DRMA stock?

New shares dilute existing holders and are often sold at a discount to the market price.

How do I read a 424B3?

The final terms of an offering of shares or bonds. Look at price, number of shares and the discount to the market price. Large offerings dilute existing shareholders.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 424B3 (prospectus (offering)): The final terms of an offering of shares or bonds.

How did DRMA stock react to this filing?

DRMA closed at $0.87 before the filing and $0.80 on Oct 21, 2026 (-8.09%). Five trading days later: $0.76 (-13.21%).

Other DRMA SEC filings

Get alerts when DRMA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

DRMA overview DRMA analysis DRMA news Latest SEC filings